Latest Healthcare Research Reports

Tag: biopharmaceutical contract manufacturing organization market top key players

  • Biopharmaceutical CMO Market Outlook Assessing Future Opportunities And Growth Prospects

    Biopharmaceutical CMO Market Outlook Assessing Future Opportunities And Growth Prospects

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    How Will The Market Value Of The Biopharmaceutical CMO Market Change Between 2026 And 2030?

    The biopharmaceutical cmo and cro market size has demonstrated significant growth in recent years. It is anticipated to increase from $35.6 billion in 2025 to $38.01 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 6.8%. The historical expansion can be attributed to several factors, including the increasing complexity of biologic drug development, rising R&D costs for biopharmaceutical companies, an expansion of clinical trial activities, the growth in biosimilar development, and the availability of specialized contract service providers.

    The biopharmaceutical cmo and cro market is projected to experience robust expansion over the coming years. By 2030, its size is anticipated to reach $48.79 billion, growing at a compound annual growth rate (CAGR) of 6.4%. This anticipated growth during the forecast period stems from factors such as a heightened demand for sophisticated biologics manufacturing, increasing capital allocation towards cell and gene therapies, the broadening scope of global clinical trial pipelines, a sharpened emphasis on strategies to accelerate market entry, and the wider integration of digitalized CRO services. Key trends characterizing the forecast horizon encompass a rise in the outsourcing of biologic drug production, an escalating need for comprehensive end-to-end contract research services, a greater emphasis on adaptable manufacturing capabilities, an expansion in support for cell and gene therapy development, and a reinforced focus on regulatory compliance services.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=7771&type=smp

    Which Significant Factors Are Encouraging Growth In The Biopharmaceutical CMO Market?

    Increased spending on research and development is projected to boost the expansion of the biopharmaceutical CMO and CRO market in the future. This surge in R&D funding stems from various elements, including a strong demand for novel solutions, intense competitive landscapes, the necessity to meet changing market requirements, and encouraging government policies. Such investments empower CMOs and CROs to develop improved manufacturing techniques and research methodologies, thereby enhancing their capabilities and operational effectiveness. This push for innovation attracts and retains customers by offering advanced solutions while simultaneously ensuring adherence to regulatory standards. For example, data from September 2025, supplied by Eurostat, the Luxembourg-based statistical agency, showed that the EU allocated approximately $456 billion USD towards research and development (R&D) in 2023 (€389 billion); this represented an increase in R&D expenditure relative to GDP, reaching 2.26% from 2.22% in the previous year. Consequently, the increasing financial commitment to research and development is fueling the expansion of the biopharmaceutical CMO and CRO market.

    How Is The Biopharmaceutical CMO Market Distributed Across Key Segments?

    The biopharmaceutical cmo market covered in this report is segmented –

    1) By Product: Biologics, Biosimilars

    2) By Source: Mammalian, Non-Mammalian

    3) By Service: Manufacturing, Fill And Finish Operations, Analytical And QC Studies, Packaging

    Subsegments:

    1) By Biologics: Monoclonal Antibodies, Recombinant Proteins, Vaccines, Cell And Gene Therapies

    2) By Biosimilars: Biosimilar Monoclonal Antibodies, Biosimilar Recombinant Proteins, Biosimilar Insulins, Biosimilar Growth Hormones

    Which Trends Are Affecting The Biopharmaceutical CMO Market Framework?

    Leading firms within the biopharmaceutical CMO and CRO market are establishing strategic alliances to bolster service offerings, boost operational effectiveness, and expedite drug development processes for biopharmaceutical entities. Such partnerships involve organizations utilizing one another’s capabilities and assets to secure shared advantages and successful outcomes. An example of this is the collaboration in June 2024 between Abzena plc., a biopharmaceutical firm from the UK, and Argonaut Manufacturing Services Inc., a US-based contract manufacturing organization (CMO), aimed at combining drug development and manufacturing solutions for their clientele. Through this alliance, their goal is to deliver swift, comprehensive drug development and manufacturing solutions designed to improve efficiency, decrease expenses, and simplify biopharmaceutical production for clients.

    Who Are The Key Market Participants In The Biopharmaceutical CMO Market?

    Major companies operating in the biopharmaceutical cmo market are Lonza Group AG, Fujifilm Diosynth Biotechnologies USA Inc., Thermo Fisher Scientific Inc., Samsung Biologics, WuXi AppTec, Catalent, Inc., Rentschler Biopharma SE, Boehringer Ingelheim, Recipharm AB, AGC Biologics, CMC Biologics, KBI Biopharma, Vetter Pharma International GmbH, Emergent BioSolutions Inc., Aenova Group, Bio-Xcellence (Boehringer Ingelheim), AbbVie Contract Manufacturing, PCI Pharma Services, Evonik Industries AG

    Access The Complete Biopharmaceutical CMO Market Report:

    https://www.thebusinessresearchcompany.com/report/biopharmaceutical-cmo-global-market-report

    Which Region Contributes The Most To The Biopharmaceutical CMO Market?

    North America was the largest region in the biopharmaceutical CMO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biopharmaceutical cmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Access Biopharmaceutical CMO Market Report for Deeper Competitive Insights

    https://www.thebusinessresearchcompany.com/customise?id=7771&type=smp

    Browse Through More Reports Similar to the Global Biopharmaceutical CMO Market 2026, By The Business Research Company

    Biopharmaceuticals Contract Manufacturing Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/biopharmaceuticals-contract-manufacturing-global-market-report

    Lyophilization Services For Biopharmaceuticals Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/lyophilization-services-for-biopharmaceuticals-global-market-report

    Biopharmaceutical Third Party Logistics Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/biopharmaceutical-third-party-logistics-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • COVID-19 saliva screening test market forecast (2026–2030)

    COVID-19 saliva screening test market forecast (2026–2030)

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    What Are The Market Size Estimates For The COVID-19 Saliva Screening Test Potential Market In 2026 And 2030?

    The potential market size for covid-19 saliva screening tests has demonstrated robust growth over recent years. This market is projected to expand from $4.28 billion in 2025 to $4.69 billion in 2026, at a compound annual growth rate (CAGR) of 9.5%. The historical growth in this sector is attributable to the discomfort associated with swab-based testing, the imperative for frequent screening, concerns regarding infection control, the demand for scalable testing solutions, and responses to public health emergencies.

    The potential market size for covid-19 saliva screening tests is expected to demonstrate significant expansion in the coming years. It is projected to achieve a value of $6.46 billion by 2030, growing at a compound annual growth rate (CAGR) of 8.4%. The impetus for this growth during the forecast period can be attributed to future pandemic preparedness strategies, the increasing prevalence of decentralized diagnostics, the expansion of workplace testing, the demand for cost-effective mass screening, and continuous innovation in saliva-based technologies. Prominent trends anticipated within the forecast period include a general shift towards non-invasive testing methods, the broadening of large-scale community screening efforts, a rising acceptance of self-collection testing, its deployment in high-traffic public locations, and its integration with comprehensive workplace safety programs.

    Access Your Free Sample Report For In-Depth Market Analysis:

    https://www.thebusinessresearchcompany.com/report/covid-19-saliva-screening-test-potential-global-market-report

    What Major Factors Are Driving The COVID-19 Saliva Screening Test Potential Market Forward?

    The rise in healthcare expenditure is anticipated to advance the growth of the COVID-19 saliva screening test potential market moving forward. Healthcare expenditure refers to the total funds dedicated to health-related products and services, including prescription drugs, hospital stays, doctor visits, medical equipment, and public health campaigns. This expenditure is escalating due to various elements like minimally invasive surgeries, cutting-edge diagnostic tools, increased research and development for new drugs, utilization of healthcare services, and specialty medications. Greater healthcare spending can offer the essential resources and backing to capitalize on the full capabilities of COVID-19 saliva screening tests, leading to more efficient pandemic management and enhanced public health outcomes. For instance, in December 2024, as per the U.S. Centers for Medicare & Medicaid Services (CMS), a US-based federal health agency, national health-care spending saw an increase of 7.5%, amounting to US $4.9 trillion, when compared to the prior year. Thus, the increasing healthcare expenditure is fueling the growth of the COVID-19 saliva screening test potential market.

    Which Segments Define The COVID-19 Saliva Screening Test Potential Market Segment Structure?

    The covid-19 saliva screening test potential market covered in this report is segmented –

    1) By Location: Travel Stations, Sports Arenas, Entertainment Venues, Corporate Campus Environments, Universities And Colleges, Factories, Other Locations

    2) By Technology: Fluorescence-Labelled Antigen, RT-PCR, CRISPR-Cas9

    3) By Mode Of Testing: Centralized Testing, Decentralized Testing

    Subsegments:

    1) By Travel Stations: Airports, Train Stations, Bus Stations, Seaports

    2) By Sports Arenas: Stadiums, Arenas, Event Halls

    3) By Entertainment Venues: Theaters, Concert Halls, Amusement Parks, Nightclubs

    4) By Corporate Campus Environments: Offices, Corporate Campuses, Business Parks

    5) By Universities And Colleges: Higher Education Campuses, Research Institutions, Student Housing Areas

    6) By Factories: Manufacturing Plants, Production Facilities, Industrial Sites

    7) By Other Locations: Healthcare Facilities, Government Buildings, Public Transportation Hubs, Shopping Centers

    Which Trends Are Impacting The Progress Of The COVID-19 Saliva Screening Test Potential Market?

    Major companies operating in the COVID-19 saliva screening test market are focused on developing innovative technologies, such as data-sharing platforms, to enhance real-time communication and collaboration among healthcare providers, laboratories, and public health authorities. This ultimately improves the efficiency and accuracy of testing, tracking, and response efforts during the pandemic. Data-sharing platforms are digital systems that facilitate the secure exchange of data among various stakeholders like healthcare providers, researchers, and organizations, enabling collaboration and information access to improve decision-making, efficiency, and outcomes across sectors. For instance, in May 2024, Mount Sinai Health System, a US-based healthcare network, launched the Center for Healthcare Readiness. This Center concentrates on improving strategies for public health emergency response, ensuring healthcare systems can effectively handle large-scale crises such as pandemics or natural disasters. It aims to enhance the capacity of the Mount Sinai Health System and collaborate with local, regional, and federal partners to develop comprehensive preparedness plans.

    Who Are The Established Players Within The COVID-19 Saliva Screening Test Potential Market?

    Major companies operating in the covid-19 saliva screening test potential market are Roche Diagnostics Corporation, Thermo Fisher Scientific Inc., Abbott Laboratories, Becton Dickinson and Company, Danaher Corporation, University of North Carolina at Chapel Hill, Hologic Inc., Beaumont Health, PerkinElmer Inc., Quidel Corporation, University of Illinois at Urbana-Champaign, Cepheid, Seegene Inc., ARUP Laboratories, Vatic Health Limited, Ambry Genetics Corporation, LumiraDx Ltd., Yale School of Public Health, Gravity Diagnostics, Psomagen Inc., Fluidigm Corporation, Phosphorus Diagnostics LLC, DxTerity Diagnostics Inc., University of Notre Dame, MOgene

    Get The Full COVID-19 Saliva Screening Test Potential Market Report:

    https://www.thebusinessresearchcompany.com/report/covid-19-saliva-screening-test-potential-global-market-report

    Which Region Holds The Highest Market Share In The COVID-19 Saliva Screening Test Potential Market?

    North America was the largest region in the COVID-19 saliva screening test potential market in 2025. The regions covered in the covid-19 saliva screening test potential market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized COVID-19 Saliva Screening Test Potential Market Report For Competitive Insights:

    https://www.thebusinessresearchcompany.com/report/covid-19-saliva-screening-test-potential-global-market-report

    Browse Through More Reports Similar to the Global COVID-19 Saliva Screening Test Potential Market 2026, By The Business Research Company

    Artificial Saliva Market Report 2026

    https://www.thebusinessresearchcompany.com/report/artificial-saliva-global-market-report

    Covid 19 Antigen Test Market Report 2026

    https://www.thebusinessresearchcompany.com/report/covid-19-antigen-test-global-market-report

    Covid 19 Rapid Test Kits Market 2026

    https://www.thebusinessresearchcompany.com/report/covid-19-rapid-test-kits-market

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Biopharmaceutical CMO market trends shaping growth over the forecast period

    Biopharmaceutical CMO market trends shaping growth over the forecast period

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    What Changes In Market Value Are Expected For The Biopharmaceutical CMO Market Over The 2026–2030 Period?

    The biopharmaceutical CMO market has observed rapid expansion in recent years. Its valuation is anticipated to climb from $28.02 billion in 2025 to $32.03 billion in 2026, achieving a compound annual growth rate (CAGR) of 14.3%. This historical growth can be linked to the escalating development of biologics pipelines, an increase in clinical trial activities, a heightened demand for adaptable manufacturing capacity, a rise in biosimilar approvals, and the presence of specialized biomanufacturing expertise.

    The biopharmaceutical cmo market size is anticipated to experience swift expansion over the coming years. This market is projected to reach $54.54 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 14.2%. This growth during the forecast period is primarily driven by escalating investments in advanced biologics, a surging need for rapid scale-up manufacturing, the broadening of personalized therapies, increasing integration of continuous bioprocessing, and a greater emphasis on risk-sharing manufacturing models. Noteworthy trends for this period encompass the increased outsourcing of biologics manufacturing, a growing requirement for biosimilar production services, wider application of single-use bioprocessing systems, the expansion of cell and gene therapy manufacturing, and a heightened focus on comprehensive, end-to-end cmo capabilities.

    Access Your Free Sample Report For In-Depth Market Analysis:

    https://www.thebusinessresearchcompany.com/report/biopharmaceutical-cmo-global-market-report

    What Key Factors Are Affecting The Biopharmaceutical CMO Market Demand?

    The expanding prevalence of chronic illnesses is anticipated to drive expansion within the biopharmaceutical CMO market in the future. These are enduring health conditions that remain throughout an individual’s life, frequently advancing gradually and necessitating continuous medical care. Biopharmaceutical CMOs are capable of improving efforts against chronic diseases by accelerating drug development, guaranteeing economical production, and upholding stringent quality benchmarks, consequently boosting the availability and economic viability of crucial medicines. For instance, in January 2024, the World Health Organization, an intergovernmental organization located in Switzerland, reported that the burden from noncommunicable diseases, primarily cardiovascular disease, cancer, chronic respiratory disease, and diabetes, continues to escalate. These diseases cause 41 million deaths annually, accounting for 74% of all deaths and the majority of premature mortality globally, with low- and middle-income countries bearing the greatest burden. Consequently, the growing prevalence of chronic diseases propels the biopharmaceutical CMOs market.

    Which Segments Define The Biopharmaceutical CMO Market Segment Structure?

    The biopharmaceutical cmo market covered in this report is segmented –

    1) By Product: Biologics, Biosimilars

    2) By Source: Mammalian, Non-Mammalian

    3) By Service: Manufacturing, Fill And Finish Operations, Analytical And QC Studies, Packaging

    Subsegments:

    1) By Biologics: Monoclonal Antibodies, Recombinant Proteins, Vaccines, Cell And Gene Therapies

    2) By Biosimilars: Biosimilar Monoclonal Antibodies, Biosimilar Recombinant Proteins, Biosimilar Insulins, Biosimilar Growth Hormones

    What Trends Are Influencing Changes In The Biopharmaceutical CMO Market?

    Leading firms within the biopharmaceutical CMO market are increasingly engaging in strategic alliances to create novel biopharmaceutical products. Such collaborations aid biopharmaceutical CMO organizations by merging assets and specialized knowledge, boosting research and development capacities, broadening market presence, and hastening product launch, which ultimately fosters innovation and expansion in the biopharmaceutical CMO sector. An example of this is the partnership formed in May 2024 between BioConnection, a contract manufacturing company situated in the Netherlands, and AGC Biologics, a contract development and manufacturing company from the US. Through this alliance, their objective is to provide an integrated and efficient solution for biopharmaceutical development and manufacturing, thereby quickening schedules and streamlining procedures for those developing drugs.

    Who Are The Established Players Within The Biopharmaceutical CMO Market?

    Major companies operating in the biopharmaceutical cmo market are Lonza Group AG, Fujifilm Diosynth Biotechnologies USA Inc., Thermo Fisher Scientific Inc., Samsung Biologics, WuXi AppTec, Catalent, Inc., Rentschler Biopharma SE, Boehringer Ingelheim, Recipharm AB, AGC Biologics, CMC Biologics, KBI Biopharma, Vetter Pharma International GmbH, Emergent BioSolutions Inc., Aenova Group, Bio-Xcellence (Boehringer Ingelheim), AbbVie Contract Manufacturing, PCI Pharma Services, Evonik Industries AG

    Get The Full Biopharmaceutical CMO Market Report:

    https://www.thebusinessresearchcompany.com/report/biopharmaceutical-cmo-global-market-report

    Where Is The Biopharmaceutical CMO Market Most Concentrated Geographically?

    North America was the largest region in the biopharmaceutical CMO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biopharmaceutical cmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Biopharmaceutical CMO Market Report For Competitive Insights:

    https://www.thebusinessresearchcompany.com/report/biopharmaceutical-cmo-global-market-report

    Browse Through More Reports Similar to the Global Biopharmaceutical CMO Market 2026, By The Business Research Company

    Pharmaceuticals Market 2026

    https://www.thebusinessresearchcompany.com/report/pharmaceuticals-market

    Medical Biomimetics Market Report 2026

    https://www.thebusinessresearchcompany.com/report/medical-biomimetics-global-market-report

    Biosimilar Market Report 2026

    https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Biopharmaceutical CMO market trends shaping growth over the forecast period

    Biopharmaceutical CMO market trends shaping growth over the forecast period

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    What Changes In Market Value Are Expected For The Biopharmaceutical CMO Market Over The 2026–2030 Period?

    The biopharmaceutical CMO market has observed rapid expansion in recent years. Its valuation is anticipated to climb from $28.02 billion in 2025 to $32.03 billion in 2026, achieving a compound annual growth rate (CAGR) of 14.3%. This historical growth can be linked to the escalating development of biologics pipelines, an increase in clinical trial activities, a heightened demand for adaptable manufacturing capacity, a rise in biosimilar approvals, and the presence of specialized biomanufacturing expertise.

    The biopharmaceutical cmo market size is anticipated to experience swift expansion over the coming years. This market is projected to reach $54.54 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 14.2%. This growth during the forecast period is primarily driven by escalating investments in advanced biologics, a surging need for rapid scale-up manufacturing, the broadening of personalized therapies, increasing integration of continuous bioprocessing, and a greater emphasis on risk-sharing manufacturing models. Noteworthy trends for this period encompass the increased outsourcing of biologics manufacturing, a growing requirement for biosimilar production services, wider application of single-use bioprocessing systems, the expansion of cell and gene therapy manufacturing, and a heightened focus on comprehensive, end-to-end cmo capabilities.

    Access Your Free Sample Report For In-Depth Market Analysis:

    https://www.thebusinessresearchcompany.com/report/biopharmaceutical-cmo-global-market-report

    What Key Factors Are Affecting The Biopharmaceutical CMO Market Demand?

    The expanding prevalence of chronic illnesses is anticipated to drive expansion within the biopharmaceutical CMO market in the future. These are enduring health conditions that remain throughout an individual’s life, frequently advancing gradually and necessitating continuous medical care. Biopharmaceutical CMOs are capable of improving efforts against chronic diseases by accelerating drug development, guaranteeing economical production, and upholding stringent quality benchmarks, consequently boosting the availability and economic viability of crucial medicines. For instance, in January 2024, the World Health Organization, an intergovernmental organization located in Switzerland, reported that the burden from noncommunicable diseases, primarily cardiovascular disease, cancer, chronic respiratory disease, and diabetes, continues to escalate. These diseases cause 41 million deaths annually, accounting for 74% of all deaths and the majority of premature mortality globally, with low- and middle-income countries bearing the greatest burden. Consequently, the growing prevalence of chronic diseases propels the biopharmaceutical CMOs market.

    Which Segments Define The Biopharmaceutical CMO Market Segment Structure?

    The biopharmaceutical cmo market covered in this report is segmented –

    1) By Product: Biologics, Biosimilars

    2) By Source: Mammalian, Non-Mammalian

    3) By Service: Manufacturing, Fill And Finish Operations, Analytical And QC Studies, Packaging

    Subsegments:

    1) By Biologics: Monoclonal Antibodies, Recombinant Proteins, Vaccines, Cell And Gene Therapies

    2) By Biosimilars: Biosimilar Monoclonal Antibodies, Biosimilar Recombinant Proteins, Biosimilar Insulins, Biosimilar Growth Hormones

    What Trends Are Influencing Changes In The Biopharmaceutical CMO Market?

    Leading firms within the biopharmaceutical CMO market are increasingly engaging in strategic alliances to create novel biopharmaceutical products. Such collaborations aid biopharmaceutical CMO organizations by merging assets and specialized knowledge, boosting research and development capacities, broadening market presence, and hastening product launch, which ultimately fosters innovation and expansion in the biopharmaceutical CMO sector. An example of this is the partnership formed in May 2024 between BioConnection, a contract manufacturing company situated in the Netherlands, and AGC Biologics, a contract development and manufacturing company from the US. Through this alliance, their objective is to provide an integrated and efficient solution for biopharmaceutical development and manufacturing, thereby quickening schedules and streamlining procedures for those developing drugs.

    Who Are The Established Players Within The Biopharmaceutical CMO Market?

    Major companies operating in the biopharmaceutical cmo market are Lonza Group AG, Fujifilm Diosynth Biotechnologies USA Inc., Thermo Fisher Scientific Inc., Samsung Biologics, WuXi AppTec, Catalent, Inc., Rentschler Biopharma SE, Boehringer Ingelheim, Recipharm AB, AGC Biologics, CMC Biologics, KBI Biopharma, Vetter Pharma International GmbH, Emergent BioSolutions Inc., Aenova Group, Bio-Xcellence (Boehringer Ingelheim), AbbVie Contract Manufacturing, PCI Pharma Services, Evonik Industries AG

    Get The Full Biopharmaceutical CMO Market Report:

    https://www.thebusinessresearchcompany.com/report/biopharmaceutical-cmo-global-market-report

    Where Is The Biopharmaceutical CMO Market Most Concentrated Geographically?

    North America was the largest region in the biopharmaceutical CMO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biopharmaceutical cmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Biopharmaceutical CMO Market Report For Competitive Insights:

    https://www.thebusinessresearchcompany.com/report/biopharmaceutical-cmo-global-market-report

    Browse Through More Reports Similar to the Global Biopharmaceutical CMO Market 2026, By The Business Research Company

    Pharmaceuticals Market 2026

    https://www.thebusinessresearchcompany.com/report/pharmaceuticals-market

    Medical Biomimetics Market Report 2026

    https://www.thebusinessresearchcompany.com/report/medical-biomimetics-global-market-report

    Biosimilar Market Report 2026

    https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Global Biopharmaceutical CMO Market Analysis for 2026–2030 with Strategic Forecast Insights for Businesses

    Global Biopharmaceutical CMO Market Analysis for 2026–2030 with Strategic Forecast Insights for Businesses

    The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

    What Market Valuation Is Forecasted For The Biopharmaceutical CMO Market By 2030 Starting From Its 2026 Size?

    The biopharmaceutical cmo market has experienced rapid growth in its size over recent years. It is projected to expand from $28.02 billion in 2025 to $32.03 billion in 2026, achieving a compound annual growth rate (CAGR) of 14.3%. This historic expansion can be linked to increasing biologics pipeline development, expansion of clinical trial activity, a rising demand for flexible manufacturing capacity, the growth of biosimilar approvals, and the availability of specialized biomanufacturing expertise.

    The biopharmaceutical CMO market size is anticipated to undergo substantial growth over the next few years. It is projected to expand to $54.54 billion by 2030, achieving a compound annual growth rate (CAGR) of 14.2%. The expansion throughout the forecast period is attributable to several factors, including increased investments in cutting-edge biologics, a surging need for accelerated scale-up manufacturing, the proliferation of personalized therapies, the increasing adoption of continuous bioprocessing, and a greater emphasis on risk-sharing manufacturing models. Noteworthy trends for the forecast period comprise an increase in the outsourcing of biologics manufacturing, a rising call for biosimilar production services, the growing application of single-use bioprocessing systems, the expansion of cell and gene therapy manufacturing, and an enhanced concentration on comprehensive CMO capabilities.

    Download the Free Sample Report to Explore Key Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=7771&type=smp

    What Primary Drivers Are Shaping The Development Of The Biopharmaceutical CMO Market?

    The increasing prevalence of chronic diseases is set to drive the expansion of the biopharmaceutical CMO market in the future. These long-term health conditions persist throughout an individual’s life, often progressing slowly and requiring continuous medical attention. Biopharmaceutical CMOs are instrumental in addressing chronic diseases by accelerating the development of drugs, providing cost-effective manufacturing solutions, and upholding high-quality benchmarks, thereby making life-saving medications more accessible and affordable. As an illustration, in January 2024, the World Health Organization, a Switzerland-based intergovernmental body, reported that the burden of noncommunicable diseases, including cardiovascular disease, cancer, chronic respiratory disease, and diabetes, continues to grow. These diseases are responsible for 41 million deaths every year, representing 74% of all deaths and the majority of premature mortality globally, with the most significant consequences observed in low- and middle-income countries. Hence, the rising burden of chronic diseases is a key driver for the biopharmaceutical CMOs market.

    Which Segment Categories Define The Biopharmaceutical CMO Market?

    The biopharmaceutical cmo market covered in this report is segmented –

    1) By Product: Biologics, Biosimilars

    2) By Source: Mammalian, Non-Mammalian

    3) By Service: Manufacturing, Fill And Finish Operations, Analytical And QC Studies, Packaging

    Subsegments:

    1) By Biologics: Monoclonal Antibodies, Recombinant Proteins, Vaccines, Cell And Gene Therapies

    2) By Biosimilars: Biosimilar Monoclonal Antibodies, Biosimilar Recombinant Proteins, Biosimilar Insulins, Biosimilar Growth Hormones

    Which Trends Are Influencing The Biopharmaceutical CMO Market?

    Leading entities within the biopharmaceutical CMO market are increasingly engaging in strategic collaborations to advance the creation of novel biopharmaceutical offerings. Such alliances prove beneficial for biopharmaceutical CMO organizations by facilitating the pooling of assets and specialized knowledge, thereby boosting research and development capacities, broadening market presence, and hastening product commercialization. This ultimately propels innovation and expansion across the biopharmaceutical CMO sector. An illustrative example occurred in May 2024, when BioConnection, a Netherlands-based contract manufacturing company, formed a partnership with AGC Biologics, a US-based contract development and manufacturing company. Through this collaboration, their objective is to offer an integrated and efficient solution for biopharmaceutical development and manufacturing, thereby shortening project durations and streamlining procedures for drug innovators.

    Who Are The Top Companies Competing In The Biopharmaceutical CMO Market?

    Major companies operating in the biopharmaceutical cmo market are Lonza Group AG, Fujifilm Diosynth Biotechnologies USA Inc., Thermo Fisher Scientific Inc., Samsung Biologics, WuXi AppTec, Catalent, Inc., Rentschler Biopharma SE, Boehringer Ingelheim, Recipharm AB, AGC Biologics, CMC Biologics, KBI Biopharma, Vetter Pharma International GmbH, Emergent BioSolutions Inc., Aenova Group, Bio-Xcellence (Boehringer Ingelheim), AbbVie Contract Manufacturing, PCI Pharma Services, Evonik Industries AG

    Read the full biopharmaceutical cmo market report here:

    https://www.thebusinessresearchcompany.com/report/biopharmaceutical-cmo-global-market-report

    How Does The Biopharmaceutical CMO Market Perform Across Major Global Regions?

    North America was the largest region in the biopharmaceutical CMO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biopharmaceutical cmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Tailored Biopharmaceutical CMO Market Research Report For Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=7771&type=smp

    Browse Through More Reports Similar to the Global Biopharmaceutical CMO Market 2026, By The Business Research Company

    Biopharmaceuticals Contract Manufacturing Global Market Report

    https://www.thebusinessresearchcompany.com/report/biopharmaceuticals-contract-manufacturing-global-market-report

    Lyophilization Services For Biopharmaceuticals Global Market Report

    https://www.thebusinessresearchcompany.com/report/lyophilization-services-for-biopharmaceuticals-global-market-report

    Biopharmaceutical Third Party Logistics Global Market Report

    https://www.thebusinessresearchcompany.com/report/biopharmaceutical-third-party-logistics-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Biopharmaceutical CMO Market 2026–2030: Forecast, Innovation, and Competitive Trends

    Biopharmaceutical CMO Market 2026–2030: Forecast, Innovation, and Competitive Trends

    Uncover key drivers, emerging technologies, and competitive movements shaping the biopharmaceutical cmo market from 2026–2035 with trusted insights from The Business Research Company

    What market expansion outlook does the Biopharmaceutical CMO Market show for the 2026–2030 period?

    The biopharmaceutical cmo market has witnessed rapid growth in recent years. Its value is anticipated to rise from $28.02 billion in 2025 to $32.03 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 14.3%. Historically, this expansion has been driven by increasing biologics pipeline development, a surge in clinical trial activity, escalating demand for flexible manufacturing capacity, a rise in biosimilar approvals, and the availability of specialized biomanufacturing expertise.

    The biopharmaceutical cmo market is poised for significant expansion in the coming years. Its size is expected to escalate to $54.54 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 14.2%. This projected growth during the forecast period stems from factors such as increasing investments in advanced biologics, a rising demand for swift scale-up manufacturing, the broadening of personalized therapies, a growing embrace of continuous bioprocessing, and an enhanced focus on risk-sharing manufacturing models. Noteworthy trends for the forecast period include a surge in the outsourcing of biologics manufacturing, increased demand for biosimilar production services, the wider adoption of single-use bioprocessing systems, the expansion of cell and gene therapy manufacturing, and a stronger emphasis on comprehensive end-to-end cmo capabilities.

    Access Your Free Sample Report for In-Depth Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=7771&type=smp

    What Drivers Are Shaping The Development Of The Biopharmaceutical CMO Market?

    The escalating prevalence of chronic conditions is anticipated to fuel expansion within the biopharmaceutical CMO market in the future. These are enduring health issues that last a lifetime, typically advancing gradually and necessitating continuous medical care. Biopharmaceutical CMOs play a crucial role in combating chronic illnesses by accelerating drug creation, providing economical manufacturing, and upholding stringent quality benchmarks, consequently boosting the availability and affordability of vital treatments. For example, in January 2024, the World Health Organization, an intergovernmental entity based in Switzerland, indicated that the load of noncommunicable diseases, predominantly cardiovascular disease, cancer, chronic respiratory disease, and diabetes, is still on the rise, causing 41 million people to die annually. This accounts for 74% of all deaths and a significant portion of early mortality globally, disproportionately affecting low- and middle-income nations. Hence, the rising incidence of chronic diseases is a key factor propelling the biopharmaceutical CMOs market.

    Which Segments Are Contributing To The Growth Of The Biopharmaceutical CMO Market?

    The biopharmaceutical cmo market covered in this report is segmented –

    1) By Product: Biologics, Biosimilars

    2) By Source: Mammalian, Non-Mammalian

    3) By Service: Manufacturing, Fill And Finish Operations, Analytical And QC Studies, Packaging

    Subsegments:

    1) By Biologics: Monoclonal Antibodies, Recombinant Proteins, Vaccines, Cell And Gene Therapies

    2) By Biosimilars: Biosimilar Monoclonal Antibodies, Biosimilar Recombinant Proteins, Biosimilar Insulins, Biosimilar Growth Hormones

    What Trends Are Expected To Impact The Competitive Landscape Of The Biopharmaceutical CMO Market?

    Leading companies in the biopharmaceutical Contract Manufacturing Organization (CMO) market are embracing strategic collaborations to produce novel biopharmaceutical items. These partnerships aid biopharmaceutical CMO firms by pooling resources and expertise, strengthening research and development proficiencies, broadening market presence, and quickening commercialization, consequently stimulating innovation and expansion within the biopharmaceutical CMO industry. For instance, in May 2024, BioConnection, a Netherlands-based contract manufacturing company, formed an alliance with AGC Biologics, a US-based contract development and manufacturing company. This collaboration aims to offer an optimized, complete solution for biopharmaceutical development and manufacturing, reducing timelines and streamlining operations for drug developers.

    Who Are The Top-Performing Companies In The Biopharmaceutical CMO Market In Recent Years?

    Major companies operating in the biopharmaceutical cmo market are Lonza Group AG, Fujifilm Diosynth Biotechnologies USA Inc., Thermo Fisher Scientific Inc., Samsung Biologics, WuXi AppTec, Catalent, Inc., Rentschler Biopharma SE, Boehringer Ingelheim, Recipharm AB, AGC Biologics, CMC Biologics, KBI Biopharma, Vetter Pharma International GmbH, Emergent BioSolutions Inc., Aenova Group, Bio-Xcellence (Boehringer Ingelheim), AbbVie Contract Manufacturing, PCI Pharma Services, Evonik Industries AG

    Access The Complete Report For Deeper Market Insights:

    https://www.thebusinessresearchcompany.com/report/biopharmaceutical-cmo-global-market-report

    Which Region Currently Holds The Largest Share Of The Biopharmaceutical CMO Market?

    North America was the largest region in the biopharmaceutical CMO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biopharmaceutical cmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request Your Customized Biopharmaceutical CMO Market Research Report for Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=7771&type=smp

    Browse Through More Reports Similar to the Global Biopharmaceutical CMO Market 2026, By The Business Research Company

    Pharmaceuticals Market 2026

    https://www.thebusinessresearchcompany.com/report/pharmaceuticals-market

    Medical Biomimetics Market Report 2026

    https://www.thebusinessresearchcompany.com/report/medical-biomimetics-global-market-report

    Biosimilar Market Report 2026

    https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • What Is The Predicted Revenue Outlook For The Global Biopharmaceutical CMO Market To Surpass $47.79 Billion?

    What Is The Predicted Revenue Outlook For The Global Biopharmaceutical CMO Market To Surpass $47.79 Billion?

    Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

    What Are The Market Size Estimates For The Biopharmaceutical CMO Market?

    The market size for biopharmaceutical CMO has seen swift expansion in the past years. The projection indicates a rise from $24.81 billion in size in 2024 up to $28.02 billion by 2025, with a compound annual growth rate (CAGR) of 12.9%. The surge during the historic phase can be linked to rising demands for biopharmaceuticals, globalization, increase in healthcare spending, regulatory backing, and a boost in research funding.

    Explosive expansion will be observed in the biopharmaceutical cmo market size in the coming years, projected to reach $47.79 billion by 2029, based on a compound annual growth rate (CAGR) of 14.3%. The growth projected over this period can be ascribed to the increased use of telehealth and remote trials, worldwide health initiatives and an increase in disposable income. Dominance in advanced therapies, digitalization, industry 4.0 revolution, continuous manufacturing and adoption of sustainable and green practices are forecasted to be the key trends over this period.

    Get A Free Sample Of The Report:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=7771&type=smp

    Which Industry Forces Are Driving The Biopharmaceutical CMO Market Forward?

    The growth of the biopharmaceutical CMO market is anticipated to be fuelled by a rise in the elderly population. Individuals who are over 60 years old are more prone to health issues such as heart attacks, strokes, coronary heart diseases, and heart failure compared to their younger counterparts. Factors such as advancements in healthcare, decreasing birth rates, and the ageing baby boomer generation contribute to the rising geriatric population. This, in turn, creates a demand for biopharmaceutical therapies aimed at treating age-related diseases, including cardiovascular disorders, and it’s here that biopharmaceutical CMOs step in by offering specialised manufacturing abilities for intricate biologics and personalised medications designed to cater to these requirements. Taking an example from the Population Reference Bureau, a non-profit organization based in the US, the number of Americans aged 65 and above is projected to increase from 58 million in 2022 to 82 million by 2050. Hence, the biopharmaceutical CMO market’s growth is being propelled by the surge in the older population.

    How Is The Biopharmaceutical CMO Market Organized By Different Segments?

    The biopharmaceutical cmomarket covered in this report is segmented –

    1) By Product: Biologics; Biosimilars

    2) By Source: Mammalian; Non-Mammalian

    3) By Service: Manufacturing; Fill And Finish Operations; Analytical And QC Studies; Packaging

    Subsegments:

    1) By Biologics: Monoclonal Antibodies; Recombinant Proteins; Vaccines; Cell and Gene Therapies

    2) By Biosimilars: Biosimilar Monoclonal Antibodies; Biosimilar Recombinant Proteins; Biosimilar Insulins; Biosimilar Growth Hormones

    What Current And Upcoming Trends Are Shaping The Biopharmaceutical CMO Market?

    Embracing technological progression is becoming a key trend in the biopharmaceutical CMO market. Notably, significant players in this niche are pushing the limits of innovation by utilizing internet of things (IoT) in their technology advancement and research endeavors. The IoT essentially utilizes networked sensors and actuators to control and monitor the environment, the objects within it, and its human interactors. These tools, integrated with manufacturing equipment and networked computer systems, can generate copious amounts of data. This data, when examined, unveils insights and opportunities for enhancing production efficiency, automating control and monitoring operations, along with facilitating adaptable manufacturing systems. For example, in February 2022, M2Cloud, based in Korea, in collaboration with Thales, a French company known for IoT communication modules, introduced an IoT-driven LTE monitoring system for overseeing biopharmaceutical processes. This practical solution provides a real-time tracking of freezers, refrigerated warehouses and even the delivery boxes in transit. All this can be done remotely by checking temperature and positional information in real time, just by switching on the power. Equipped with such cutting-edge technologies specifically designed for biopharmaceutical operations, the safety of pharmaceutical products increases significantly.

    Who Are The Primary Market Leaders In The Biopharmaceutical CMO Market?

    Major companies operating in the biopharmaceutical cmo market include Lonza Group AG, Fujifilm Diosynth Biotechnologies USA Inc., Thermo Fisher Scientific Inc., Samsung Biologics, WuXi AppTec, Catalent, Inc., Rentschler Biopharma SE, Boehringer Ingelheim, Recipharm AB, AGC Biologics, CMC Biologics, KBI Biopharma, Vetter Pharma International GmbH, Emergent BioSolutions Inc., Aenova Group, Synlogic, Inc., MedImmune (AstraZeneca), BioLife Sciences, Bio-Xcellence (Boehringer Ingelheim), AbbVie Contract Manufacturing, PCI Pharma Services, AltheaDx, Daxor Corporation, Genomatica, Inc., Astellas Pharma, Juno Therapeutics (Celgene), Medpace, Celerion, Evonik Industries AG

    Access The Complete Report Here:

    https://www.thebusinessresearchcompany.com/report/biopharmaceutical-cmo-global-market-report

    How Do Regional Dynamics Influence The Biopharmaceutical CMO Market Performance?

    North America was the largest region in the biopharmaceutical CMO market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biopharmaceutical cmo market report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

    Customize Your Report Here:

    https://www.thebusinessresearchcompany.com/customise?id=7771&type=smp

    Browse Through More Reports Similar to the Global Biopharmaceutical CMO Market 2025, By The Business Research Company

    Animal And Pet Food Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/animal-and-pet-food-global-market-report

    Greenhouse Nursery And Flowers Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/greenhouse-nursery-and-flowers-global-market-report

    Crop Production Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/crop-production-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Biopharmaceutical CMO Industry Insights: Market Forecast to 2029

    Biopharmaceutical CMO Industry Insights: Market Forecast to 2029

    Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

    How Is The Biopharmaceutical CMO Market Size Likely To Evolve From 2025 Through 2034?

    The biopharmaceutical cmo market size has seen rapid expansion in recent years. It is forecast to grow from $24.81 billion in 2024 to $28.02 billion in 2025, at a compound annual growth rate (CAGR) of 12.9%. This historical growth can be attributed to factors including increasing demand for biopharmaceuticals, globalization, a rise in healthcare expenditure, regulatory support, and increased research funding.

    The biopharmaceutical cmo market size is projected to experience rapid growth in the coming years, with an expected increase to $47.79 billion by 2029, achieving a compound annual growth rate (CAGR) of 14.3%. The expansion anticipated during this forecast period can be attributed to various factors including the rise in telehealth and remote trials, global health initiatives, an increase in disposable income, and further global health initiatives. Prominent trends throughout this period are expected to include the dominance of advanced therapies, the integration of digitalization and Industry 4.0, the adoption of continuous manufacturing, and a focus on sustainability and green practices.

    Unlock Your Free Sample Report for Exclusive Market Data:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=7771&type=smp

    Which Industry Drivers Are Expected To Accelerate The Biopharmaceutical CMO Market From 2025 To 2029?

    The rising elderly population is projected to boost the biopharmaceutical CMO market’s expansion. Individuals over 60 years old face a higher risk of experiencing cardiovascular events like heart attacks, strokes, and the development of coronary heart disease and heart failure compared to younger demographics. This growth in the older demographic is a result of improved healthcare, decreasing birth rates, and the aging process of the baby boomer generation. The expanding geriatric population is fueling the need for biopharmaceutical treatments designed for age-associated conditions, including cardiovascular disorders. In this context, biopharmaceutical CMOs are crucial, offering specialized production capacities for intricate biologics and customized medications to meet these requirements. For example, data from January 2024, reported by the US-based non-profit organization, Population Reference Bureau, indicates that the population of Americans aged 65 and older is projected to increase from 58 million in 2022 to 82 million by 2050. Consequently, the growing geriatric population is a key driver for the biopharmaceutical CMO market’s expansion.

    What Are The Major Segments Identified In The Biopharmaceutical CMO Market?

    The biopharmaceutical cmomarket covered in this report is segmented –

    1) By Product: Biologics; Biosimilars

    2) By Source: Mammalian; Non-Mammalian

    3) By Service: Manufacturing; Fill And Finish Operations; Analytical And QC Studies; Packaging

    Subsegments:

    1) By Biologics: Monoclonal Antibodies; Recombinant Proteins; Vaccines; Cell and Gene Therapies

    2) By Biosimilars: Biosimilar Monoclonal Antibodies; Biosimilar Recombinant Proteins; Biosimilar Insulins; Biosimilar Growth Hormones

    Which Competitive Trends Are Defining The Biopharmaceutical CMO Market Structure?

    Technological advancement represents a significant trend gaining traction within the biopharmaceutical CMO market. Major companies in this market are making progress in their new technologies and research and development efforts utilizing IoT. The Internet of Things (IoT) involves the application of networked sensors and actuators to regulate and observe the environment, the objects moving within it, and the individuals operating within it. A considerable amount of data can be generated by sensors, actuators, and other components integrated into manufacturing machinery and networked computer systems. This data can be analyzed to gain insights and identify opportunities to improve production efficiency, automate monitoring and control functions, and enable adaptable manufacturing systems. For instance, in February 2022, M2Cloud, a Korea-based bio-cold chain technology company, collaborated with Thales, a France-based firm specializing in IoT communication modules, to develop an IoT-based LTE monitoring system for biopharmaceutical monitoring. This system is valuable for real-time surveillance of freezers, refrigerated warehouses, and similar facilities, alongside tracking delivery boxes in real-time. It enables remote verification of temperature and position information instantly by simply powering it on. With technologies specifically designed for biopharmaceutical management, it enhances the safety of pharmaceutical products.

    Which Major Industry Participants Are Leading The Biopharmaceutical CMO Market Growth?

    Major companies operating in the biopharmaceutical cmo market include Lonza Group AG, Fujifilm Diosynth Biotechnologies USA Inc., Thermo Fisher Scientific Inc., Samsung Biologics, WuXi AppTec, Catalent, Inc., Rentschler Biopharma SE, Boehringer Ingelheim, Recipharm AB, AGC Biologics, CMC Biologics, KBI Biopharma, Vetter Pharma International GmbH, Emergent BioSolutions Inc., Aenova Group, Synlogic, Inc., MedImmune (AstraZeneca), BioLife Sciences, Bio-Xcellence (Boehringer Ingelheim), AbbVie Contract Manufacturing, PCI Pharma Services, AltheaDx, Daxor Corporation, Genomatica, Inc., Astellas Pharma, Juno Therapeutics (Celgene), Medpace, Celerion, Evonik Industries AG

    Download The Full Report For Exclusive Market Findings:

    https://www.thebusinessresearchcompany.com/report/biopharmaceutical-cmo-global-market-report

    How Do Regional Market Performances Compare Within The Biopharmaceutical CMO Industry?

    North America was the largest region in the biopharmaceutical CMO market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biopharmaceutical cmo market report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

    Request A Customized Version Of The Biopharmaceutical CMO Market Report:

    https://www.thebusinessresearchcompany.com/customise?id=7771&type=smp

    Browse Through More Reports Similar to the Global Biopharmaceutical CMO Market 2025, By The Business Research Company

    Animal And Pet Food Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/animal-and-pet-food-global-market-report

    Greenhouse Nursery And Flowers Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/greenhouse-nursery-and-flowers-global-market-report

    Crop Production Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/crop-production-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Biopharmaceutical CMO Industry Insights: Market Forecast to 2029

    Biopharmaceutical CMO Industry Insights: Market Forecast to 2029

    Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

    How Is The Biopharmaceutical CMO Market Size Likely To Evolve From 2025 Through 2034?

    The biopharmaceutical cmo market size has seen rapid expansion in recent years. It is forecast to grow from $24.81 billion in 2024 to $28.02 billion in 2025, at a compound annual growth rate (CAGR) of 12.9%. This historical growth can be attributed to factors including increasing demand for biopharmaceuticals, globalization, a rise in healthcare expenditure, regulatory support, and increased research funding.

    The biopharmaceutical cmo market size is projected to experience rapid growth in the coming years, with an expected increase to $47.79 billion by 2029, achieving a compound annual growth rate (CAGR) of 14.3%. The expansion anticipated during this forecast period can be attributed to various factors including the rise in telehealth and remote trials, global health initiatives, an increase in disposable income, and further global health initiatives. Prominent trends throughout this period are expected to include the dominance of advanced therapies, the integration of digitalization and Industry 4.0, the adoption of continuous manufacturing, and a focus on sustainability and green practices.

    Unlock Your Free Sample Report for Exclusive Market Data:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=7771&type=smp

    Which Industry Drivers Are Expected To Accelerate The Biopharmaceutical CMO Market From 2025 To 2029?

    The rising elderly population is projected to boost the biopharmaceutical CMO market’s expansion. Individuals over 60 years old face a higher risk of experiencing cardiovascular events like heart attacks, strokes, and the development of coronary heart disease and heart failure compared to younger demographics. This growth in the older demographic is a result of improved healthcare, decreasing birth rates, and the aging process of the baby boomer generation. The expanding geriatric population is fueling the need for biopharmaceutical treatments designed for age-associated conditions, including cardiovascular disorders. In this context, biopharmaceutical CMOs are crucial, offering specialized production capacities for intricate biologics and customized medications to meet these requirements. For example, data from January 2024, reported by the US-based non-profit organization, Population Reference Bureau, indicates that the population of Americans aged 65 and older is projected to increase from 58 million in 2022 to 82 million by 2050. Consequently, the growing geriatric population is a key driver for the biopharmaceutical CMO market’s expansion.

    What Are The Major Segments Identified In The Biopharmaceutical CMO Market?

    The biopharmaceutical cmomarket covered in this report is segmented –

    1) By Product: Biologics; Biosimilars

    2) By Source: Mammalian; Non-Mammalian

    3) By Service: Manufacturing; Fill And Finish Operations; Analytical And QC Studies; Packaging

    Subsegments:

    1) By Biologics: Monoclonal Antibodies; Recombinant Proteins; Vaccines; Cell and Gene Therapies

    2) By Biosimilars: Biosimilar Monoclonal Antibodies; Biosimilar Recombinant Proteins; Biosimilar Insulins; Biosimilar Growth Hormones

    Which Competitive Trends Are Defining The Biopharmaceutical CMO Market Structure?

    Technological advancement represents a significant trend gaining traction within the biopharmaceutical CMO market. Major companies in this market are making progress in their new technologies and research and development efforts utilizing IoT. The Internet of Things (IoT) involves the application of networked sensors and actuators to regulate and observe the environment, the objects moving within it, and the individuals operating within it. A considerable amount of data can be generated by sensors, actuators, and other components integrated into manufacturing machinery and networked computer systems. This data can be analyzed to gain insights and identify opportunities to improve production efficiency, automate monitoring and control functions, and enable adaptable manufacturing systems. For instance, in February 2022, M2Cloud, a Korea-based bio-cold chain technology company, collaborated with Thales, a France-based firm specializing in IoT communication modules, to develop an IoT-based LTE monitoring system for biopharmaceutical monitoring. This system is valuable for real-time surveillance of freezers, refrigerated warehouses, and similar facilities, alongside tracking delivery boxes in real-time. It enables remote verification of temperature and position information instantly by simply powering it on. With technologies specifically designed for biopharmaceutical management, it enhances the safety of pharmaceutical products.

    Which Major Industry Participants Are Leading The Biopharmaceutical CMO Market Growth?

    Major companies operating in the biopharmaceutical cmo market include Lonza Group AG, Fujifilm Diosynth Biotechnologies USA Inc., Thermo Fisher Scientific Inc., Samsung Biologics, WuXi AppTec, Catalent, Inc., Rentschler Biopharma SE, Boehringer Ingelheim, Recipharm AB, AGC Biologics, CMC Biologics, KBI Biopharma, Vetter Pharma International GmbH, Emergent BioSolutions Inc., Aenova Group, Synlogic, Inc., MedImmune (AstraZeneca), BioLife Sciences, Bio-Xcellence (Boehringer Ingelheim), AbbVie Contract Manufacturing, PCI Pharma Services, AltheaDx, Daxor Corporation, Genomatica, Inc., Astellas Pharma, Juno Therapeutics (Celgene), Medpace, Celerion, Evonik Industries AG

    Download The Full Report For Exclusive Market Findings:

    https://www.thebusinessresearchcompany.com/report/biopharmaceutical-cmo-global-market-report

    How Do Regional Market Performances Compare Within The Biopharmaceutical CMO Industry?

    North America was the largest region in the biopharmaceutical CMO market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biopharmaceutical cmo market report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

    Request A Customized Version Of The Biopharmaceutical CMO Market Report:

    https://www.thebusinessresearchcompany.com/customise?id=7771&type=smp

    Browse Through More Reports Similar to the Global Biopharmaceutical CMO Market 2025, By The Business Research Company

    Animal And Pet Food Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/animal-and-pet-food-global-market-report

    Greenhouse Nursery And Flowers Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/greenhouse-nursery-and-flowers-global-market-report

    Crop Production Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/crop-production-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Biopharmaceutical CMO Market in Focus: Forecasting Growth Drivers, Scaling Potential, and Global Opportunities

    Biopharmaceutical CMO Market in Focus: Forecasting Growth Drivers, Scaling Potential, and Global Opportunities

    Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

    What Are the Key Milestones in the Biopharmaceutical CMO Market’s Growth Trajectory From 2025 To 2034?

    The market size of the biopharmaceutical CMO has seen swift growth in the past few years. The market size is projected to rise from $24.81 billion in 2024 to $28.02 billion in 2025, representing a compound annual growth rate (CAGR) of 12.9%. Factors that contributed to this growth in the historical period include the escalating demand for biopharmaceuticals, globalization, rising healthcare expenditures, regulatory backing, and enhanced research funding.

    Expectations are high for the biopharmaceutical CMO market size to surge rapidly in the upcoming years. The projected value stands at$47.79 billion by 2029, escalating at a compound annual growth rate (CAGR) of 14.3%. The anticipated expansion in the forecast period can be linked to factors like the emergence of telehealth and remote trials, global health initiatives, and increased disposable income. The forecast period will also likely witness significant trends such as dominance of advanced therapies, digitalization coupled with industry 4.0, continuous manufacturing, and the adoption of sustainability and green practices.

    Download a free sample to assess the report’s scope and structure:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=7771&type=smp

    What Are the Core Market Drivers Propelling Growth in the Biopharmaceutical CMO Industry?

    The growth of the biopharmaceutical CMO market is anticipated to be propelled by the growing geriatric population. Those who are aged over 60 are typically more susceptible to heart conditions, including heart attacks, strokes, coronary heart disease, and heart failure, as compared to the younger populace. Factors such as improved healthcare services, the decrease in birth rates, and the aging baby boomer generation are all contributing to the increasing aging population. This growth in the geriatric demographic is amplifying the need for biopharmaceutical therapies that target age-related diseases, especially cardiovascular disorders. Biopharmaceutical CMOs are crucial in this scenario as they offer specialised manufacturing expertise for complex biologics and customised medicines to cater to these requirements. For instance, the Population Reference Bureau, a non-profit organization based in the US, estimated in January 2024 that the population of Americans aged 65 and over, which stood at 58 million in 2022, is projected to escalate to 82 million by 2050. Thus, the demographic shift towards an older population continues to be a catalyst for the growth of the biopharmaceutical CMO market.

    How Is the Biopharmaceutical CMO Market Segmented?

    The biopharmaceutical cmomarket covered in this report is segmented –

    1) By Product: Biologics; Biosimilars

    2) By Source: Mammalian; Non-Mammalian

    3) By Service: Manufacturing; Fill And Finish Operations; Analytical And QC Studies; Packaging

    Subsegments:

    1) By Biologics: Monoclonal Antibodies; Recombinant Proteins; Vaccines; Cell and Gene Therapies

    2) By Biosimilars: Biosimilar Monoclonal Antibodies; Biosimilar Recombinant Proteins; Biosimilar Insulins; Biosimilar Growth Hormones

    Request customized data on this market:

    https://www.thebusinessresearchcompany.com/customise?id=7771&type=smp

    Which Regions Are Driving the Next Phase of the Biopharmaceutical CMO Market Growth?

    North America was the largest region in the biopharmaceutical CMO market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biopharmaceutical cmo market report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

    What Key Market Trends and Innovations Are Shaping the Future of the Biopharmaceutical CMO Industry?

    The rise of technological innovations is a major trend that is becoming increasingly prevalent in the biopharmaceutical CMO industry. Leading companies in this sector are harnessing new technologies and focusing on research and development aided by IoT. IoT, or the Internet of Things, involves the use of networked sensors and actuators to monitor and control environments, objects, and individuals within these environments. This technology can generate a vast amount of data from embedded sensors, actuators, and other components in manufacturing machinery and computer systems. This data offers valuable insights and opportunities for enhancing production efficiency, automating monitoring and control operations, and facilitating adaptable manufacturing systems. For example, M2Cloud, an enterprise based in Korea and specializing in bio-cold chain technology, teamed up with Thales, an IoT communication module specialist from France, in February 2022 to create an IoT-based LTE system for biopharmaceutical monitoring. This system broadens the scope of real-time monitoring to encompass freezers, refrigerated warehouses, and even the real-time tracking of delivery boxes. The only requirement to remotely check temperature and location information in real time is power. With technologies specifically developed for managing biopharmaceuticals, the safety and integrity of pharmaceutical products can be significantly increased.

    View the full report here:

    https://www.thebusinessresearchcompany.com/report/biopharmaceutical-cmo-global-market-report

    How Is the Biopharmaceutical CMO Market Defined and What Are Its Core Parameters?

    Biopharmaceutical CMO is a business that provides manufacturing services, with the capacity to produce small quantities for preclinical research and development and more significant numbers needed for clinical trials and commercialization. The biopharmaceutical CMO assists in lowering overall operational risk and time to market.

    Purchase the full report and get a swift delivery:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=7771

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Europe +44 7882 955267

    Asia & Others +44 7882 955267 & +91 8897263534

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model